Latest Conference Articles

Pharmacists can address social determinants to improve patient well-being and treatment.

Challenges in treating insomnia in special groups and resistant cases, and ways for pharmacists to improve outcomes.

Linking strong anticholinergic medications to increased risk of dementia in older adults

Social determinants of health can worsen mental health disorders such as depression, but the effect of depression can also negatively impact social determinants of health.

In March 2024, the label for bempedoic acid was expanded to reduce cardiovascular risk and expand the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients.

Potential for integration into care and future advancements for gaps in current schizophrenia treatments

Current evidence and data regarding clozapine-resistant schizophrenia is unclear, but new treatment options are on the horizon that could show promise.

Although there are medical considerations for patients with psychiatric conditions, prescribers must consider patient preference to increase adherence and effectiveness of contraception.

The finding did not reach statistical significance in the primary composite endpoint.

Data for generalized anxiety disorders and cannabis use is scarce, but pharmacists can help educate patients on potential benefits and risks of cannabis usage.

Expert perspective on current research, treatment approaches, and clinical considerations for pharmacologic management of borderline personality disorder

Potential adjunctive and novel treatment options based on a patient's specific symptoms and clinical factors are being explored to treat treatment-resistant schizophrenia

The abstracts will be presented at the American College of Cardiology Conference from April 6 to April 8, 2024, in Atlanta, Georgia.

Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.

The results further confirm earlier findings from the EMPA-KIDNEY trial.

Although the number of clinical trials has quadrupled, the number of FDA approvals remains stable over a 10-year period, highlighting workforce challenges in clinical research.

These FDA-approved therapies are used to treat lymphoma after 2 or more lines of therapy and represent significant advancements in the treatment of lymphoma.

FDA-approved BiTE therapies for relapsed/refractory multiple myeloma show promising response rates, offering off-the-shelf alternatives to CAR T therapy.

Despite being a Schedule I drug, cannabis is increasingly used in oncology for symptom management, although data remains limited.

Lisa Janssen Carlson, PharmD, BCOP, discusses some background and history of regulations for the conduct of clinical trials.

Pharmacy Times will be at the American Association of Psychiatric Pharmacists (AAPP) Annual Meeting in Orlando, Florida from April 7 to April 10, 2024.

Precision medicine revolutionized NSCLC treatment, targeting specific mutations like KRAS G12C with therapies such as adagrasib to improve patient outcomes.

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

Pharmacists play a pivotal role working alongside the DEA and OIG in enforcing and preventing drug diversion nationally.

An FDA executive discusses the Surgeon General’s recommendations for promoting mental health and wellbeing for employees in the workplace.

A pharmacist discusses the impact of comprehensive weight management with a shared decision making approach.

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Studies have shown that the presence of advanced pharmacy technicians in a pharmacy has a positive predictive validity to increased monthly immunizations.